CD274 and neoplasm: Unlike PD-L1 immunohistochemistry, tumor mutational burden (TMB), or mismatch repair/microsatellite instability (MMR/MSI) testing, which have shown variable predictive performance and are limited by tumor type, biopsy access, and genomic complexity, CiRT delivers a universally applicable, blood-based classifier with a binary output that is easy to interpret and implement in routine oncology practice.